The COX-2 Gene and the Immune System

Launched by NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS) · Aug 30, 2012

Keywords

ClinConnect Summary

This is a cross-sectional, controlled study designed to investigate the association of single nucleotide polymorphisms (SNPs) in the cyclooxygenase-2 (COX2) gene, also called prostaglandin endoperoxidase synthase 2 (PTGS2), on T-cell differentiation and function. Specifically, the impact of the promoter-region SNP 765G\>C (rs20417) and the 3 untranslated region (UTR) SNP 8473T\>C (rs5275) on T helper cell (Th) 2, Th9, and Th17 differentiation and function will be examined. Non-Hispanic, White or Black/African American, non-pregnant adults, aged 18-65 years, who are wild type (WT), with resp...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Participant of the Environmental Polymorphisms Registry and current contact information available
• * Genotype information available for relevant 765G\>C and 8473T\>C COX2 polymorphisms, which indicates:
• • Individuals who are WT with respect to both 765G\>C and 8473T\>C (N=31)
• • Individuals who are WT with respect to 765G\>C and homozygous for 8473T\>C (N=31)
• • Individuals who are homozygous for both 765G\>C and 8473T\>C (N=31)
• • Age 18- 65 years
• • Race self-identified as White or Black and Non-Hispanic ethnicity
• • Willing and able to provide informed consent
• • Able to comply with all protocol procedures
• EXCLUSION CRITERIA:
• • History of infection within the preceding 1 week or an oral temperature \>38 degrees C
• • Current daily or chronic use of corticosteroids (systemic, inhaled and topical).
• • Any current conditions known to impact peripheral white blood cell count (e.g., leukemia, lymphopenia, AIDS, other immunodeficiency disorders)
• • Current daily or chronic use of systemic immunosuppressants.
• • Current pregnancy or lactation
• * Unwilling or unable to:
• • Fast (including alcohol and caffeine-containing products) and discontinue tobacco use for 12 hours prior to the study visit
• • Withhold all prescribed and over-the-counter medications and supplements the morning of the study visit, until after the visit is completed
• * Refrain from taking the following medications and supplements for 7 days prior to the study visit:
• • NSAIDs
• • Corticosteroids (nasal, inhaled, topical or systemic)
• • Fish oil and niacin supplements
• • For blood draws that exceed 200ml, a hematocrit of \<34% for women or \<36% for men, or \>56% for either gender.
• • For blood draws exceeding 200ml, blood or plasma donation in the last 8 weeks